Materials engineering for immunomodulation by Hubbell, Jeffrey A. et al.
1Institute of Bioengineering, 2Institute of Chemical Sciences and Engineering, École Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland.
Materials engineering for 
immunomodulation
Jeffrey A. Hubbell1,2, Susan N. Thomas1 & Melody A. Swartz1,2
The engineering of materials that can modulate the immune system is an emerging field that is developing 
alongside immunology. For therapeutic ends such as vaccine development, materials are now being engineered 
to deliver antigens through specific intracellular pathways, allowing better control of the way in which antigens 
are presented to one of the key types of immune cell, T cells. Materials are also being designed as adjuvants, to 
mimic specific ‘danger’ signals in order to manipulate the resultant cytokine environment, which influences how 
antigens are interpreted by T cells. In addition to offering the potential for medical advances, immunomodulatory 
materials can form well-defined model systems, helping to provide new insight into basic immunobiology. 
The term ‘immunobioengineering’ is used to describe efforts by immu-
nologists and engineers to design materials, delivery vehicles and 
molecules both to manipulate and to better understand the immune 
system. Examples are the engineering of material surfaces to induce or 
prevent complement activation, the engineering of adjuvants to activate 
the immune system, the engineering of antigen or adjuvant carriers for 
subunit vaccine delivery, and the engineering of microenvironments to 
determine the interaction kinetics of mature dendritic cells and naive 
T cells. These advances not only will contribute to prophylactic vaccine 
strategies for infectious diseases but also are likely to affect immuno-
therapeutics, particularly for cancer, and new approaches to prevent or 
treat allergies and autoimmune diseases. The field is rapidly evolving 
along with advances in our understanding of immunology and is also 
contributing to our knowledge of basic immunology.
In this Review, we describe the current state of immunobioengi-
neering as it intersects with the field of materials science, and we give 
a perspective on its current and future directions. We focus on materi-
als for immunomodulation, particularly with respect to dendritic-cell 
modulation. We begin by providing a brief introduction to the targets 
for delivery: the types of cell that materials are being designed to target, 
the tissues in which those cells reside, the intracellular compartments 
within those cells, and the influence that delivery to those particular 
compartments has on immunological outcome. We then discuss the bio-
molecular payloads used to activate immune cells and the design of the 
materials used to deliver those ‘danger’ signals along with, in the context 
of vaccination, antigens. Finally, we highlight materials approaches that 
are being developed to explore basic immunological function, especially 
how dendritic cells and T cells interact.
Tissue and cellular targets
As the general goals of immunobioengineering are to probe and manip-
ulate the immune system, we start with a general discussion of tissue, 
cellular and subcellular targets — what we want to target and why — to 
guide the design principles discussed below.
The immune cells most frequently targeted include B cells, macro-
phages and dendritic cells, which are all effective antigen-presenting cells 
(APCs)1. Dendritic cells are typically considered the most specialized, 
because they present antigen to their cognate naive T-cell partners and 
instruct them what do with it (for example induce anergy, tolerance or 
immunity)2. They are the main focus of this Review, although recent evi-
dence points to basophils being an important APC involved in T helper 2 
(TH2)-cell immunity3.
In the most simplistic, classic view, dendritic cells remain in an imma-
ture state while sampling antigens in their environment to present to 
T cells for the maintenance of self-tolerance (that is, they present anti-
gen without costimulatory molecules); this includes in the lymph node, 
where functionally immature dendritic cells sample antigens drained 
with lymph from the periphery4. When they encounter pathogenic or 
endogenous danger signals (described below) or adjuvants (as engi-
neered danger signals) while taking up antigen, they begin to mature and 
express the chemokine receptor CCR7, which allows them to migrate 
into the nearest draining lymphatic vessels and then to the lymph node5. 
There, they present processed antigenic peptides with maturation-
induced costimulatory molecules to T cells to initiate an adaptive, or 
antigen-specific, immune response.
Thus, in this simplistic view, antigen presented by immature dendritic 
cells (in the presence of transforming growth factor-β1 (TGF-β1) and 
interleukin-10 (IL-10)) maintains tolerogenic responses (Fig. 1a), whereas 
that presented by mature dendritic cells in the presence of immunogenic 
cytokines can lead to immunogenic T cells. In reality, there are exceptions: 
mature dendritic cells can induce tolerogenic responses, and there are 
‘partially mature’ dendritic cells, whose function is poorly understood1.
Moreover, there are many subsets of dendritic cells, including the fol-
lowing: plasmacytoid dendritic cells, which secrete interferon-α (IFN-α); 
myeloid dendritic cells, which can secrete large amounts of IL-12; fol-
licular dendritic cells, which do not express major histocompatibility 
complex (MHC) class II molecules; lymphoid dendritic cells, which can 
secrete large amounts of IFN-γ; CD8− or CD8+ dendritic cells, of which 
the former do not carry the CD8 antigen and the latter do; and several 
tissue-specific subtypes such as Langerhans cells. Although still poorly 
understood, these subtypes can be specialized for different functions, 
such as antigen ‘cross-presentation’ by CD8+DEC205+ dendritic cells 
(DEC205 also known as LY75) residing in the splenic T-cell zone, or 
MHC class II presentation by CD8− dendritic cells residing in the red 
pulp6. Much of what we know about dendritic-cell behaviour comes 
from in vitro studies using dendritic cells derived from peripheral blood 
monocytes, haematopoietic progenitor cells or bone marrow; these cells 
are typically differentiated into immature dendritic cells by using IL-4 
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Figure 1 | Design principles for activating 
antigen-specific CD4+ T cells. To activate 
naive CD4+ (helper) T cells, the T-cell antigen 
receptor needs to recognize antigen that has 
been loaded onto MHC class II molecules and 
presented by dendritic cells. The response of the 
T cells depends not only on this receptor–ligand 
interaction but also on costimulatory molecules 
being presented by the dendritic cells and on the 
cytokine environment during activation. a, In 
normal surveillance mode, dendritic cells in 
their immature state constantly pick up antigen 
and present it, without costimulatory molecules, 
to T cells. This leads to T-cell anergy (that is, 
the T cell cannot receive further signals) and/
or activation of inducible (FOXP3+) regulatory 
T (Treg) cells when the cytokines TGF-β1 and 
IL-10 are present. Treg cells themselves secrete 
TGF-β1 and IL-10, which inhibit TH1 cells. In 
fact, all types of T cell can secrete IL-10. b, By 
contrast, when dendritic cells that have been 
activated by pattern-recognition receptor (PRR) 
ligation and maturation signals from microbial 
products present antigen to T cells together with 
costimulatory molecules, they can drive a TH1-, 
TH2- or TH17-cell response. For example, at the 
early stages of bacterial or viral infection, antigen 
presentation occurs in a microenvironment that 
contains IL-6 and IL-23 (but no IL-4), stimulating 
naive CD4+ T cells to differentiate into TH17 
cells. These cells secrete IL-6, IL-22 (which 
induces epithelial cells to produce antimicrobial 
peptides) and IL-17 (which activates local 
fibroblasts). The fibroblasts, in turn, attract 
neutrophils and macrophages through the 
secretion of cytokines such as GM-CSF and IL-6 
and chemokines such as CXCL8 and CXCL12. 
c, At later stages of infection, these activated 
neutrophils and macrophages, in turn, secrete 
the chemokines CCL3, CCL4 and CCL5, which 
attract additional T cells and promote the 
differentiation of CD4+ T cells into TH1 cells. A 
TH1-cell response occurs when dendritic cells 
mature in the presence of cytokines such as 
TNF-α and GM-CSF and when PRRs such as Toll-
like receptors (TLRs) are activated by microbial 
products, leading to IL-12 secretion. IL-12 is a 
key cytokine for TH1-cell activation, which can 
be enhanced by IFN-γ. TH1 cells secrete IFN-γ, 
which (in addition to promoting further TH1-
cell activation) activates natural killer (NK) cells 
and inhibits the activation of TH2 and TH17 cells. 
TH1 cells also produce TNF-α, as well as IL-2 and 
lymphotoxin-α, all of which can drive B cells to 
differentiate into opsonizing-antibody-producing 
plasma cells (which predominantly produce IgG). 
Under certain conditions, IL-10 is secreted by TH1 
cells as an inhibitory feedback regulator. d, TH2-
cell responses are elicited when dendritic cells 
present antigen in the presence of IL-4, which 
is secreted by TH2 cells themselves and inhibits 
TH17 cells. TH2 cells also secrete IL-5, which 
together with IL-4 stimulates B-cell proliferation 
and antibody production (especially antibody of 
the classes IgM, IgA and IgE). Other cytokines 
secreted by TH2 cells include IL-6, IL-9, IL-13 and 
IL-10, the last of which inhibits IFN-γ production 
by TH1 cells and IL-12 production by dendritic 
cells. Therefore, when engineering immune 
responses, it is important to consider the cytokine 
microenvironment, in addition to how the 
antigen will be presented by dendritic cells, both 
of which can be modulated by PRR signalling and 
uptake mechanisms.
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and granulocyte–macrophage colony-stimulating factor (GM-CSF, 
also known as CSF2) and matured by using lipopolysaccharide (LPS) 
or tumour-necrosis factor-α (TNF-α). Therefore, care must be taken in 
translating in vitro data from generic ‘dendritic cells’ to the in vivo situa-
tion, with an appreciation for tissue-specific dendritic-cell subsets, and 
it should be noted that there are many differences between such subsets 
in rodents and those in humans.
The response that a dendritic cell elicits depends on many factors, 
including the state of maturation of the cell, how the antigen was taken 
up and processed by the cell, and even the tissue in which the cell was 
activated. Antigens presented in the context of MHC class I molecules are 
recognized only by CD8+ T cells, whereas those bound to MHC class II 
molecules are recognized by CD4+ T cells. Dendritic cells, classically 
CD8+ dendritic cells, can present antigen in the context of both classes 
of MHC molecule. Some of these complex interactions with CD4+ T cells 
are illustrated in Fig. 1 and described in Table 1. Importantly, the cytokine 
environment in which both dendritic-cell activation and communication 
between dendritic cells and CD4+ T cells occurs can control the response 
and should be considered when choosing tissue targets. These cytokines 
can be secreted by dendritic cells on activation or inactivation, by the acti-
vated CD4+ T cells themselves, by neutrophils and macrophages recruited 
to the inflammatory site and, finally, by stromal cells that can become acti-
vated during inflammation. Because the cytokine profile present during 
contact with the dendritic cell can determine CD4+ T-cell fate, engineering 
approaches that manipulate or make use of the cytokine environment 
are important design considerations. For example, a biomaterials vac-
cine platform in which IL-10 expression was knocked down using short 
interfering RNA has been explored, showing strongly positive effects; from 
Fig. 1 and Table 1, it is evident that this was done to block the inhibitory 
role that IL-10 has in TH1-cell and TH2-cell development7.
APCs traffic through almost every tissue in the body. Generally 
speaking, epithelial tissues have strong immunosurveillance activity, 
as they form barriers to the outside world through which most patho-
genic entry occurs. In peripheral tissues such as the skin, Langerhans 
cells, other dendritic cells and macrophages detect danger signal and 
antigens, signal other immune cells to the site by means of chemokine 
secretion and migrate to the nearest draining lymph node to activate 
an immune response. Most traditional vaccines delivered in the skin or 
muscle target such cells, including those vaccines formulated in alum 
(the standard adjuvant, which consists of particulate aluminium phos-
phates; described further below), an adjuvant that targets peripheral 
APCs through its ‘depot effect’. The skin, lungs, gut and lymph nodes 
are common target tissues for both natural immunomodulatory agents 
and prophylactic or therapeutic ones, and different immune responses 
can be achieved in different target tissues8.
The lymph node is an emerging target tissue of interest. Dendritic 
cells and B cells reside in the lymph nodes, and T cells traffic through the 
paracortical region, the architecture of which is optimized for rapid cell 
trafficking to help naive T cells to make contact with thousands of den-
dritic cells to find their APC partners9. Immature dendritic cells patrol 
peripheral tissues and then migrate to the lymph nodes after they take 
up antigen, but the lymph nodes also contain many immature dendritic 
cells that constantly sample antigens carried through the lymph nodes 
by lymph drained from the peripheral tissues; the latter population of 
dendritic cells may function mainly for the purpose of maintaining tol-
erance4. However, when these immature lymph-node dendritic cells 
were exposed to antigen together with a maturation stimulus, they were 
able to activate T cells, suggesting that lymph-node dendritic cells could 
be potential targets for immunomodulatory agents4 (approaches for tar-
geting the lymph node are described below). Also, it has been shown 
that dendritic-cell presentation of peptide-antigen-loaded MHC class II 
molecules in the draining lymph node of a tissue following subcutaneous 
antigen delivery came in two discrete stages: first, by the lymph-node 
dendritic cells, which acquired antigen in the lymph node; and, second, 
by the dendritic cells that had migrated there from the injection site10.
Further in support of the lymph node as a target, the humoral 
response is apparently initiated by lymph-node B cells, which take up 
antigen directly in the lymph-node follicles, rather than by migrating 
B cells or by dendritic cells, indicating that lymph-node targeting may 
be advantageous for protective antibody-generating vaccines11. This 
approach has not been widely investigated, and it remains to be deter-
mined how the T-cell response differs when initiated by peripherally 
activated dendritic cells and when initiated by lymph-node dendritic 
cells, as well as how the chemokine balance shifts in the lymph node 
and how this ultimately affects the long-term response. This is par-
ticularly important in light of emerging evidence demonstrating the 
importance of lymph-node T-cell homing in tolerogenesis12,13. Thus, 
although lymph-node targeting for immunomodulation has interesting 
prospects, much more research is needed.
The mucosal epithelia are a major site of immunosurveillance, 
responding to most immune challenges encountered by an organism. 
The mucosae of the airways, the digestive tract and the vagina, among 
others, contain special lymphoid tissues, referred to as the mucosa-asso-
ciated lymphoid tissues. In these tissues, antigens are collected by micro-
fold (M) cells and transferred to dendritic cells, which in collaboration 
with T cells induce a specialized humoral response of secretory IgA 
in the mucosal secretions, as well as a cellular response14. Much of the 
protective response of the mucosa derives from secretory IgA. Systemic 
vaccination, for example by intramuscular injection, does not typically 
induce strong mucosal immunity, whereas vaccination of the mucosa 
does, although in a region-specific manner14. Given the importance of 
inducing mucosal immunity and protection against the vast number 
of pathogens that enter through these routes, the different mucosae 
are important tissue targets, and the M cells and dendritic cells in the 
mucosa-associated lymphoid tissues are important cellular targets14.
In addition to understanding the tissue and cellular targets for immuno-
therapeutics, it is important to understand the subcellular targets. APCs 
process antigen from the cytosol or following endocytosis for display in 
MHC class I molecules and/or MHC class II molecules, respectively15. 
Intracellular proteins (for example those produced by viral pathogens) are 
degraded by the proteasome, released into the cytosol and subsequently 
translocated into the endoplasmic reticulum by the transporter associated 
with antigen processing (TAP) to be loaded into the peptide-binding site 
of MHC class I molecules1. By contrast, proteins internalized from the 
Table 1 | Influence of the cytokine microenvironment on immune responses
Desired response Cytokine environment of 
dendritic-cell activation
Cytokines produced 
by activated 
dendritic cells
Cytokines produced 
by activated 
T cells
Effect on other cells Natural inducers
Treg cell High TGF-β1 and IL-10; 
low IL-6 and IL-12
TGF-β1 IL-10 Suppresses CD4+ and CD8+ T-cell proliferation Self antigens
TH17 cell IL-23, high TGF-β1 and 
high IL-6
TNF-α IL-17, IL-22 and 
IL-6
Activates fibroblasts to produce IL-6, G-CSF, GM-CSF, 
CXCL8 and CXCL12, which attract neutrophils and 
macrophages, creating a TH1-cytokine microenvironment
Bacterial and viral 
infections
TH1 cell IL-12, IL-18 and IL-27 IL-12 IFN-γ, IL-2 and 
lymphotoxin-α
Blocks TH17- and TH2-cell development; 
activates B cells to produce IgG1 (in humans)
Bacterial and viral 
infections
TH2 cell IL-4 and IL-6 IL-1 IL-4, IL-5, IL-6, 
IL-9, IL-10 and 
IL-13
Induces B-cell proliferation and antibody class 
switching; promotes Treg-cell development; activates 
macrophages (through the alternative pathway)
Helminth infections
451
NATURE|Vol 462|26 November 2009 REVIEW INSIGHT
449-460 Insight - Hubbell NS.indd   451 19/11/09   16:39:57
© 2009 Macmillan Publishers Limited. All rights reserved
extracellular environment (for example from phagocytosed bacteria) are 
digested in endolysosomes, and peptides derived from these are loaded 
onto MHC class II molecules, which are then transported to the plasma 
membrane1. Some subsets of dendritic cells, classically CD8+ dendritic 
cells, can also efficiently present exogenously obtained peptides on MHC 
class I molecules, a process known as cross-presentation, making dendritic 
cells unique among the APCs (macrophages can also cross-present anti-
gen but with much lower efficiency1). As mentioned above, CD8+ T cells 
are primed by interactions between the T-cell antigen receptors (TCRs) of 
CD8+ T cells and MHC class I molecules, and CD4+ T cells are primed by 
the binding of their TCRs to MHC class II molecules. Therefore, the choice 
of the route of antigen delivery, and thus which class of MHC molecule 
presents the antigen, directly (but not solely, as the nature of dendritic-cell 
activation by danger signals is also important) controls the type of antigen-
specific T-cell response that is obtained. These presentation pathways, in 
their simplest and most classic form, are illustrated in Fig. 2.
Materials as tools to modulate immune-cell function
As mentioned, APCs — in particular dendritic cells — are responsible 
for integrating a myriad of external biomolecular stimuli to produce 
an adaptive immune response. Antigen presentation leads to immuno-
genicity only when costimulatory molecules are presented with the 
MHC-class-I-associated or MHC-class-II-associated peptide antigen. 
Thus, to interpret what to do with the antigen, dendritic cells use recep-
tor systems, such as pattern-recognition receptors (PRRs), that can sense 
either pathogen-derived or endogenous danger signals16,17. A pathogen 
may be recognized by several PRRs either simultaneously or sequen-
tially, activating distinct or shared signalling pathways. How the den-
dritic cell responds, and therefore the quality of the induced adaptive 
immunity, is determined by the danger signals to which the dendritic 
cell is exposed17.
PRRs largely recognize pathogen-derived biomolecules referred to 
as pathogen-associated molecular patterns (PAMPs), which are evo-
lutionarily distant non-self molecules such as LPS and viral double-
stranded RNA18. Many endogenous molecules can also trigger PRR 
activation; such molecules, known as danger-associated molecular pat-
terns (DAMPs), are typically associated with tissue damage or distress. 
A select group of ligands for a few representative PRRs, along with the 
immunological responses they induce, are described in Table 2.
Recognition of PAMPs and DAMPs by PRRs occurs both through 
extracellular activation cascades such as the complement system and 
through intracellular signalling pathways that can be initiated at the 
dendritic-cell surface, in the endosome after phagocytosis or in the 
cytosol16. PRR expression patterns vary significantly between subcellular 
Figure 2 | Design principles for targeting the intracellular pathways of 
dendritic cells to modulate antigen presentation. A simplified view of 
antigen presentation by dendritic cells. Left, exogenous particles, proteins 
or pathogens can be taken into the cell through various pathways, including 
phagocytosis (for particles >1 μm), macropinocytosis (<1 μm), and 
endocytosis from caveolae (~60 nm) or clathrin-coated pits (~120 nm). 
Exogenous antigens are then processed in endocytic vesicles (phagosomes, 
endosomes, lysosomes and/or endolysosomes; dashed arrows represent 
multiple vesicular steps). Processed antigen (peptide) is subsequently loaded 
onto MHC class II molecules (which have been assembled in the endoplasmic 
reticulum, transported through the Golgi apparatus and targeted to endocytic 
compartments) in a lysosome or MHC class II compartment (MIIC). The 
peptide–MHC class II complexes then move through exocytic vesicles to 
the cell surface, where antigen presentation occurs. MHC class II loading 
of endogenous antigen provided by autophagy can also occur, particularly 
when the cell is under stress. Right, antigen can be loaded onto MHC class I 
molecules through two main pathways. In the classical pathway, endogenous 
or viral proteins in the cytosol are processed through the proteasome, 
transported into the endoplasmic reticulum through the molecule TAP 
(transporter associated with antigen processing), loaded onto MHC class I 
molecules, and then transported through the Golgi apparatus and exocytic 
vesicles to the cell surface for presentation. In addition, exogenous antigens 
that have been phagocytosed, macropinocytosed or endocytosed can be 
cross-presented on MHC class I molecules by some subsets of dendritic cell. 
In this pathway, antigen either may be loaded in endocytic compartments 
(not shown) or may escape endosomes and arrive in the cytosol, where it 
is processed through the proteasome as usual, loaded onto MHC class I 
molecules and transported to the surface. Finally, terminal degradation 
pathways can occur (for example when apoptotic cells are internalized). See 
refs 1 and 96–98 for details about antigen processing. 
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compartments, immune-cell types and subtypes, and tissues16,19. One of 
the major PRR classes is the Toll-like receptor (TLR) family, members 
of which recognize a large number of pathogen-derived ligands and a 
smaller number of endogenously derived ligands. Of the TLRs, some 
— such as TLR4 and TLR2, which recognize LPS and lipo teichoic acid 
respectively — may be expressed on the plasma membrane. By contrast, 
others — such as TLR7, TLR8 and TLR9, which recognize bacterial RNA 
or DNA16 — may be present in the endosomal compartment. Many 
other intracellular and membrane-expressed PRRs are involved in the 
recognition of viral nucleic acids or bacterial and fungal carbohydrates 
by dendritic cells; these include cytosolic NOD-like receptors (such as 
NALP3), which activate the dendritic-cell inflammasome in response 
to bacterial and endogenous danger signals16. Again, the dendritic cell 
integrates these signals to determine whether to mature, how to process 
and present the antigen, and which cytokines to produce.
For these reasons, one important task in immunobioengineering is 
to develop delivery strategies by which to present antigen — along with 
PAMPs to ligate particular PRRs — so as to induce a desirable TH1-type 
or TH2-type adaptive immune response. We contemplate the targeting 
and penetration of barriers as objectives for materials design: the barrier 
of the antigen being able to find, or being found by, the APCs that reside 
in the tissues performing surveillance for signals of infection, the bar-
rier of the tissue interstitium after injection of antigen into connective 
tissue such as skin, the barrier of the mucosa after antigen is sprayed 
into the nasal sinus or inhaled into the lungs, the barrier of entry to 
the endolysosomal compartment of the cell after endocytosis, and the 
barrier of entry to the cytosol presented by the endosomal membrane. 
Materials with different design principles and characteristics are being 
developed to accomplish these delivery tasks.
Materials for enhancing antigen uptake by APCs
Materials design considerations for enhancing uptake by APCs have 
focused on recognition and recruitment. With regard to recognition, 
some subclasses of dendritic cell possess an endocytic receptor, DEC205 
(ref. 20), which has been successfully used to enhance dendritic-cell 
uptake, for example with an antigen or a biomaterial particle conjugated 
to anti-DEC205 antibodies21,22. Recruitment involves chemoattracting 
other APCs to the delivery site, and strategies include the use, variously, 
Table 2 | Examples of PRRs, their PAMP ligands and associated immune responses
PRR Ligand Associated immune response Synthetic analogue Biomaterials engineering approaches Induced immune response
TLRs
TLR3 Double-stranded 
RNA
Induces type I IFNs and 
pro-inflammatory cytokines 
(TNF-α, IL-6 and IL-12)16,85
Poly(I:C)55 pH-sensitive biodegradable 
polyketals co-encapsulating ion-
paired protein antigen and poly(I:C) 
into ~1–3-μm-diameter particles55
Increased the number of IFN-γ-producing 
antigen-specific CD8+ T cells; elicited TNF-α 
and IL-2 production by CD8+ T cells in vitro55
Biodegradable 
poly(d,l-lactide-co-glycolide) 
microspheres co-encapsulating 
protein antigen with poly(I:C)79
Increased the number of IFN-γ-producing 
antigen-specific CD8+ T cells in vivo79
TLR4 LPS Induces IL-6, IL-12 and 
TNF-α; upregulates 
costimulatory molecule and 
type I IFN production by 
dendritic cells16,86
Tetra-acyl lipid A80 Poly(lactic-co-glycolic acid) 
nanoparticles co-encapsulating 
tumour-associated protein 
antigen and tetra-acyl lipid A80
Increased the number of IFN-γ-producing 
antigen-specific CD8+ T cells; induced 
production of pro-inflammatory cytokines 
(TNF-α, IL-12, IFN-γ, IL-2 and IL-6) at the 
tumour site80
TLR5 Flagellin Induces strong IgM and 
IgG responses87
Recombinant 
flagellin domains88
Poly(methyl vinyl ether-co-maleic 
anhydride) nanoparticles coated 
with flagella-enriched extract89
Not determined
TLR7 Single-stranded 
RNA
Induces IFN-α, IL-12 and 
TNF-α; recruits dendritic 
cells and cytotoxic T cells; 
increases T-cell activation 
by APCs90
Imiquimod91 Imiquimod administered 
immediately after delivery of 
plasmid DNA coated onto 
2-μm-diameter gold particles91
Increased the number of mature dendritic 
cells in draining lymph nodes; enhanced 
antigen-specific CD4+ and CD8+ T-cell 
responses, biased towards a predominance 
of TH1 cells91
TLR9 Unmethylated 
bacterial DNA
Activates immune cells 
and cytokine production for 
strong TH1-type responses92
CpG 
oligonucleotides79,92
Biodegradable 
poly(d,l-lactide-co-glycolide) 
microspheres co-encapsulating 
protein antigen with CpG 
oligonucleotides79
Increased the number of IFN-γ-producing 
antigen-specific CD8+ T cells and the 
level of cytolysis; improved protection 
against vaccinia virus infection compared 
with separately administered antigen and 
adjuvant79
NALPs
NALP3 Particulate matter 
such as asbestos, 
silica or alum
Induces pro-inflammatory 
cytokine (IL-1β)93
Polymeric 
microparticles64
Biodegradable 
poly(d,l-lactide-co-glycolide) 
and polystyrene microparticles 
administered in conjunction with 
protein antigen64
Increased the secretion of IL-1β by dendritic 
cells; induced higher antibody titres; elicited 
IL-6 production by T cells; recruited and 
activated CD11b+Gr1− cells in vivo64
Complement-associated
C3 Carbohydrates 
and bacterial 
proteins
Induces pathogen 
clearance by opsonization
of pathogens94
Polymeric 
materials containing 
nucleophiles28
Complement-activating, 
nucleophile-containing 
polymeric nanoparticles28
Induced antigen-specific monoclonal 
antibody; induced IFN-γ-producing antigen-
specific CD8+ T cells28
Recombinant 
C3d72,95
Recombinant, trimeric C3d 
protein conjugated to protein 
antigen through an avidin 
bridge18
Induced a more robust and protective 
response to antigen when administered with 
IFA than when protein antigen administered 
in IFA or with alum18
Recombinant, trimeric C3d–
antigen fusion DNA vaccine95
Generated higher-binding, early-appearing 
and neutralizing antibody responses; 
increased the number of IFN-γ-producing 
antigen-specific CD8+ T cells95
The responses shown are related to engineering approaches to triggering these pathways or types of immunity using biomaterials. The table is not comprehensive but highlights a few recent biomaterials-
based strategies for immunotherapeutic applications. C3, complement component 3; IFA, incomplete Freund’s adjuvant; NALP3, NACHT domain-, leucine-rich repeat- and PYD-containing protein 3; 
poly(I:C), polyinosinic acid/polycytidylic acid.
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of degradable polyester particles to create gradients of dendritic-cell 
chemoattractants23, injectable hydrogels24, and degradable scaffolds that 
simultaneously release cytokines, PAMPs and antigen25. As an extreme 
example, cell transplantation approaches involve isolating dendritic cells 
from a subject, exposing them to antigen in vitro (referred to as ‘load-
ing’), stimulating them and then re-implanting them26.
Materials for penetrating tissue barriers
Whereas the section above describes approaches to delivering the den-
dritic cell to a material by targeting, recruitment or transplantation, 
approaches are also being explored to take the material directly to the 
endogenous dendritic cells in the draining lymph node after injection 
into the tissue interstitium, with particle size being the primary material 
control parameter. In most tissues, there exists a slow interstitial flow 
from the blood capillaries to the lymphatic capillaries, of the order of 
0.1–1 μm s−1 (ref. 27). It is through this interstitial flow that macro-
molecules are swept into the lymphatics, and that immature lymph-
node dendritic cells (and follicular B cells, as described earlier11) can 
sample self molecules and pathogen-derived molecules present in the 
tissues. This approach to targeting APCs is highly robust, as long as the 
immunotherapeutic particles are neither too big (resulting in entrap-
ment in the interstitium) nor too small (resulting in absorption into 
the blood). The dependence of targeting on size has been probed with 
biomaterial nanoparticles sterically stabilized with polyethylene glycol 
(PEG) brushes: particles of ~20–25 nm in diameter were very efficiently 
delivered to lymph nodes; particles of 45–50 nm in diameter were some-
what less efficiently delivered (64%, plus the 20–25-nm nanoparticles); 
and particles of 100 nm in diameter were poorly delivered (8%, plus 
the smaller particles)28. It is interesting to compare these sizes with 
those of viruses: the smallest viruses (for example the single-stranded 
DNA parvovirus or the RNA picornaviruses such as poliovirus) are 
in the 20–30-nm range, but most are substantially larger (for exam-
ple adenoviruses, 70–80 nm; retroviruses, 100–200 nm; and poxvirus, 
100 × 200 × 300 nm3)29. As described below, it is possible to use materi-
als chemistry to access sizes as low as, and even smaller than, those of 
biological viruses.
Three general material-fabrication schemes are useful for forming 
polymer nanoparticles in the 20–30-nm range: emulsion polymeriza-
tion, self-assembly and branched-polymer synthesis (other techniques 
are available for inorganic nanoparticles). These schemes are illustrated 
in Fig. 3. In emulsion polymerization30, surfactant micelles are formed in 
an aqueous environment, and hydrophobic monomer is loaded within 
the micelle and polymerized. The result is a surfactant-stabilized poly-
mer nanoparticle, the size distribution of which can be controlled by 
the ratio of surfactant to monomer. The particles contain a hydrophobic 
core within a hydrophilic corona (from the surfactant), to the surface 
of which hydrophilic molecules such as antigens and PAMPs may be 
conjugated31. Useful surfactants include block co-polymers, such as 
PEG-bl-polypropylene glycol-bl-PEG, also known as Pluronics28.
Self-assembly is a powerful method for forming very small particles. 
In principle, the size distribution of particles formed by self-assembly 
can be very narrow, owing to the potential to approach equilibrium. Typ-
ically, amphiphilic block co-polymers are dissolved in a water-miscible 
organic medium that is a solvent for both block compositions, and this 
solution is subsequently dropped into water, which is a solvent for one 
block but not the other, forcing micellization with the hydrophobic block 
at the core of the micelle. Polymer micelles are intrinsically unstable 
structures that can disassemble after the infinite dilution that follows 
injection into the body, driving considerations of how to engineer an 
optimal dissociation rate.
The hydrophobicity of the core-forming block is an important con-
sideration; for example, the critical micelle concentration of block 
co-polymers containing polypropylene glycol (such as Pluronics) is not 
as favourable (low) as that of analogous block co-polymers containing 
polypropylene sulphide (PPS), in which the oxygen atoms in the poly-
mer backbone of polypropylene glycol have been replaced with sulphur 
atoms32. Using this materials chemistry, it is possible to access the sub-
viral size range; for example, PEG44-bl-PPS10 forms spherical micelles 
that have 7-nm cores and 14-nm total diameters33 and that demonstrate 
slow dissociation. Alternatively, very high-molecular-weight polypro-
pylene glycol (the hydrophobic block) in Pluronics micelles can serve 
as a stabilizing influence34.
In addition to hydrophobicity, and the molecular size of the hydro-
phobe in a self-assembling block co-polymer, the melting tempera-
ture (Tm) and the glass-transition temperature (Tg) are important. On 
the one hand, low-Tg polymers have the advantage of being readily 
formed at normal production temperatures, thus approaching equilib-
rium micelle size and shape; on the other hand, higher-Tg hydrophobic 
block compositions (Tg >37 °C) or crystalline hydrophobic polymers 
(Tm >37 °C) self-assemble at supraphysiological temperatures for very 
stable use at 37 °C, below Tg or Tm. Micelle, and also polymersome35 (see 
below), processability can thus be engineered by manipulating any of 
the mat erial parameters mentioned above to exploit the equilibrium 
nature of the materials, as well as by slowing the dissociation rate to 
suit practical use.
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Figure 3 | Means of forming polymeric nanoparticles. a, Emulsion 
polymerization is carried out in a continuous phase, with an emulsifier, 
here shown as an ABA block co-polymer (A in purple, and B in green), 
surrounding monomer droplets (centre). The surfactant PEG-bl-
polypropylene glycol-bl-PEG is a convenient emulsifier, in that the terminal 
hydroxyls on the polymer may be used for antigen grafting (not shown), for 
example as in ref. 28. b, Self-assembly of amphiphilic block co-polymers can 
yield very small nanoparticles (as depicted). Diameters of less than 15 nm 
have been achieved33 using PEG-bl-polypropylene sulphide (PEG-bl-PPS). 
c, Even smaller structures for antigen display can be formed by synthesizing 
branched polymers, such as the dendrimer depicted. For further examples 
of dendrimers, see ref. 37. In all panels, antigen and danger signals may be 
attached to the nanoparticle surfaces. Note that the structure in c is much 
smaller than those in a and b. 
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Biologically derived molecules may also readily self-assemble, as can 
be observed in virus-like particles, which are now in clinical use. Virus-
like particles are biotechnologically produced, self-assembled structures 
of viral capsid proteins and can approach the 50-nm diameter range36. 
Heterologous production of the viral capsid proteins ensures their self-
assembly without a viral genome, and self-assembled protein particles 
therefore possess the great advantage of biological functionality and 
intrinsic immunoreactivity, without the potential for infectivity. As these 
materials are biologically derived, however, they are more expensive and 
can be stored less stably than synthetic materials. Nevertheless, they are 
clinically highly effective and serve as an excellent model to be mimicked 
by biomaterials scientists.
Branched polymers, especially dendrimers, have been developed as 
very small nanoparticles to display antigen and danger signals37. The 
advantages of branched-polymer strategies include the stability ensured 
by the covalent bonds within the polymer and a very narrow size distri-
bution due to the nature of their synthesis. This synthesis is performed 
stepwise from a multifunctional initial scaffold, by adding difunctional 
monomer in serial couple–deprotect steps. Thus, the number of end 
groups on the dendrimer doubles with each serial step. As well-char-
acterized display systems of well-defined and controllable size, these 
materials have great potential as vaccine platforms38.
Other materials design considerations for polymer particles intended 
for eventual therapeutic use relate to materials stability and elimination. 
Although a degradation mechanism is necessary, ensuring stability dur-
ing storage is paramount. It is very difficult to dry and then resuspend 
nanoparticles at their original size distribution; moreover, gentle drying 
processes such as lyophilization are expensive, which may hinder the 
use of a vaccine form in global applications. Therefore, storage in water, 
preferably without refrigeration, is an important design goal. Promising 
materials chemistries have been explored to engineer nanoparticles that 
degrade either by oxidation or reduction (requiring that the nanopar-
ticles be stored in a controlled atmosphere, which is inexpensive) or by 
pH-triggered hydrolysis (requiring storage at a stable pH). Also, simple 
dissociation to form unimolecular final products of a molecular weight 
low enough for renal clearance (less than ~10,000 g mol−1) is a feasible 
approach (requiring storage above the critical micelle concentration)39. 
These and other chemistries will be introduced in more detail below.
Materials for penetrating mucosal barriers
Mucosal surfaces present a target for vaccination that is both appealing 
and challenging. Most pathogens invade the body through a mucosal 
route, be it the nasal cavity, the airways, the gut, the vagina or the rectum; 
therefore, establishment of a secretory IgA immune response in these 
tissues would be especially beneficial for providing protection. Delivery 
of vaccines to these surfaces is substantially complicated by the mucosal 
layer that otherwise protects them, at least in part, against pathogen 
entry. The mucus consists of a physically crosslinked, viscoelastic hydro-
gel, with mesh sizes of the order of 10–100 nm (ref. 40). Barrier penetra-
tion is largely restricted for particles that are greater in diameter than 
a few hundred nanometres40,41, although particles that are ~50 nm in 
diameter can diffuse in mucus almost as freely as they do in water40.
Particle surface properties have a major role in particle penetration of 
mucus. It has been observed that even very large particles, 200–500 nm in 
diameter, can penetrate mucus when appropriately grafted with surface 
PEG chains42. This effect depends strongly on the molecular weight of the 
grafted PEG, with grafts comprising shorter chains (2,000 g mol−1) pene-
trating well but those comprising longer chains (10,000 g mol−1) penetrat-
ing several orders of magnitude more slowly. The field of mucoadhesion 
has been explored from a polymer science perspective: surface-tethered 
polymer chains interpenetrate, and entangle within, the mucin polymer 
network, leading to adhesion associated with entanglement and disentan-
glement43, and longer chains interpenetrate more effectively than shorter 
ones44. These concepts are illustrated in Fig. 4. Here, muco adhesion is 
not beneficial, as the vaccine particles become entrapped in the mucosal 
barrier; therefore, PEG chains long enough to prevent adsorption, but 
not long enough to lead to entanglement, are desired.
Gene vectors, which are useful in DNA vaccination (that is, with the 
antigen being expressed from the delivered DNA), present a particular 
challenge in mucosal penetration, in that most nanoparticle complexes 
containing DNA are formed with cationic carriers, such as cationic lip-
ids; these cationic charges can dramatically limit particle transit through 
the negatively charged mucous layer45. Cationic lipid mixtures have been 
developed with PEG-grafted lipid components to enhance particle pen-
etration46, although the polymer chains may interfere with later pro-
cesses of endosomal destabilization and gene uptake. To address this, 
vectors with PEG chains that are removed by cellular processes (see the 
next section) during endosomal processing are being investigated47.
Materials for intracellular targeting
As described above, the detection of both antigens and danger signals 
is complex and takes place in different compartments of the cell. For 
example, antigens for presentation by MHC class I pathways must be 
available within the cytosol, whereas those for presentation by MHC 
class II molecules must be present within the endolysosomal compart-
ment (Fig. 2). With regard to danger signals for APC activation, even 
considering just the TLR family, receptors for some ligands (such as 
hydrophobic bacterial cell-wall components, which bind to TLR4, or 
bacterial flagellae components, which bind to TLR5) are present on 
the plasma membrane, whereas receptors for others (single-stranded 
RNA, which binds to TLR7, or unmethylated bac terial CpG DNA, 
which binds to TLR9) are present and active within the endolysosome. 
The spatial details of antigen and danger-signal delivery are therefore 
important. Several polymers that accomplish endolysosomal delivery 
are described below and are shown in Fig. 5.
A number of chemical reactions have been engineered to release par-
ticle payload within the endolysosomal compartments. As the antigen 
in the endosomal vesicles is processed and the vesicles mature towards 
lysosomal fusion, the intravesicular pH is lowered, first to a pH of ~6 
in the endosome and then to a pH of ~5 in the lysosome, relative to 
the extracellular pH, 7.4. Additionally, the reduction–oxidation state 
of these compartments changes: the endosome is rendered reductive, 
whereas the lysosomal compartment is substantially oxidative, com-
pared with the mildly oxidative extracellular environment. For these 
reasons, both pH-sensitive and reduction–oxidation-sensitive materials 
are being studied.
Oxidation at low pH represents the final stages of endolysosomal 
processing, with exposure in the lysosome to a number of reactive oxy-
gen species. Oxidation-sensitive dissociation of self-assembling block 
co-polymers has been engineered, by designing block co-polymers 
(mentioned above) containing a hydrophobic PPS block; on exposure 
to oxidative conditions, the block is converted to hydrophilic poly-
propylene sulphoxide and, ultimately, to the more hydrophilic polypro-
pylene sulphone48. When block co-polymer architectures are selected 
a b
Figure 4 | Steric stabilization versus entanglement in mucus. Nanoparticles 
need to gain access to the mucosal epithelia for antigen delivery or 
transfection, so they must be able to penetrate the mucous layer. The 
grafting of polymers such as PEG (pink) to nanoparticles (yellow) has been 
explored as a way of blocking the adsorption of particles to components 
of the mucus (green). Studies into mucosal bioadhesion have examined 
various physical regimes of polymers. Shorter, denser graft layers tend to 
sterically stabilize the nanoparticle surface (a). By contrast, longer, sparser 
grafts allow interpenetration of the two polymers (the grafted chains 
and the mucous network) (b), leading to adhesion to the mucus43,44,99 and 
unfavourable nanoparticle penetration42,100.
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with approximately equal block volumes, so as to form vesicles known as 
polymersomes, on oxidation the polymersomes transform into worm-
like micelles, then into spherical micelles and finally into soluble poly-
mer, as the ratio of the effective volumes of the hydrophobic block and 
the hydrophilic regions decreases eventually to zero49, releasing the 
contents of the polymersome.
Earlier in the processes of endolysosomal processing, endocytosed 
nanoparticles encounter a reductive environment. Self-assembling block 
co-polymers with architecture PEG-SS-PPS, that is with a reducible disul-
phide connection between the hydrophobic and hydrophilic blocks, have 
been shown to destabilize within 15 min of endocytosis in a macrophage-
like cell line (a model of APCs), releasing the contents of the polymersomes 
within the early endosome35. Linear multiblock co-polymers have also 
been developed; they consist of DNA-binding peptides that are flanked 
on each side by a cysteine residue and polymerized by oxidation in vitro50. 
The resultant linear, high-molecular-weight polymer binds DNA and 
condenses it into a nanoparticle, referred to as a polyplex, but reduction 
within the endosome leads to multiple chain scission to form products that 
bind only weakly to DNA, thereby releasing the material. If endosomal 
disruption is also accomplished (see below), efficient transfection with 
antigen-encoding DNA can be achieved50. Moreover, if nucleotide-based 
PAMPs, such as CpG oligonucleotides, are included, efficient delivery to 
the endosomal receptors can be achieved. Low-molecular-weight disul-
phide peptides have also been used to good effect as reduction-sensitive 
crosslinkers for the endosomal release of polyplexes51.
The pH gradient experienced during endolysosomal processing has also 
been used for endosomal release. Whereas simple degradable polyesters 
such as polylactic acid, polyglycolic acid and their co-polymers are 
degraded by acid-catalysed hydrolysis, the hydrolysis rates at even 
lysosomal pH are so slow that they are not very useful for endosomal 
delivery. For this reason, more acid-sensitive, hydrolytically sensitive 
links, such as orthoesters52 and ketals53, have been sought. For example, 
particles crosslinked with ketal moieties have been developed for bio-
molecular delivery53, including vaccination54, through the targeting of 
endosomal release. Endosomal release of CpG oligonucleotides has also 
been shown to be feasible using these materials chemistries55. Degrada-
tion rates at lysosomal pH can be ~20-fold faster than at extracellular 
pH55, providing the desired trigger.
Whereas the endosomal compartment is the interesting target for 
MHC class II loading, MHC class I presentation requires the antigen 
payload to be present in the cytosol. Thus, disruption of the endosomal 
membrane barrier to access the cytosol is an important target. Endo-
somal disruption is also necessary for DNA vaccination, in which plas-
mid DNA must be expressed to produce the antigen. Materials schemes 
that have been investigated for these purposes are illustrated in Fig. 6.
Both reductive and pH triggers have been used to control endosomal 
escape. With regard to reduction, the polymer fragments produced by 
reduction of the PEG-SS-PPS block co-polymers mentioned above 
apparently possessed sufficient surface activity to disrupt the endosomal 
membrane, making the payload available within the endosome within 
15 min but within the cytosol within 2 h (ref. 35). Triggers sensitive to 
pH are more commonly sought. One approach involves the engineer-
ing of polymers that express pH-dependent surface activity and thus 
membrane-disruptive activity, for example polypropyl acrylic acid; these 
polymers display no membrane-disruptive activity at extracellular pH, 
but at pH 6–6.5 are strongly membranolytic56. These polymers have 
demonstrated strong potential for antigen delivery, processing, and pres-
entation by MHC class I molecules56. Oligocations and polycations can 
also destabilize the cell membrane; cationic cell-penetrating peptides 
based on oligoarginine have been incorporated in pH-sensitive ketal-
crosslinked nanoparticles — the membranolytic moieties becoming 
available as the pH is lowered and hydrolysis proceeds — with beneficial 
effect for intracellular accumulation57.
Polycations can have an additional favourable effect on membrane 
destabilization, owing to an osmotic imbalance that ensues during 
their pro tonation. Polyethylene imine possesses a favourable pKa value 
for pro tonation within the endosome, the associated osmotic effect being 
referred to as the ‘proton-sponge’ effect58. The use of such polymers is, 
however, hampered by cytotoxicity associated with polyethylene imine’s 
contact with the cell’s membranes. To retain the proton-sponge effect 
yet eliminate cytotoxicity, core–shell nanoparticles have been studied 
using sequential emulsion polymerization, first of a secondary-amine-
containing monomer of appropriate pKa (diethylaminoethyl meth-
acrylate), to form a core, and then of a second monomer, to form a 
corona (or shell)59. Regional separation of the functions of the particle 
led to favourable cytosolic release, through endosomal disruption by 
means of the proton-sponge effect, with markedly lower cytotoxicity 
than caused by free polyethylene imine60.
Materials interaction with, and penetration of, cell membranes to access 
the cytosol is complex, involving hydrophobic as well as electrostatic inter-
actions. One new class of particle has demonstrated intriguing potential, 
based on an intrinsic membrane-penetrating ability derived from its spa-
tial distributions of hydrophobicity and charge. Each particle consists of a 
spatially heterogeneous organic adsorbed layer formed atop a 6-nm gold 
nanoparticle to create <1-nm striations of hydrophobicity and negative 
charge61. These particles, but not those with the same overall charge den-
sity but lacking the striations, were able to pass directly through the plasma 
membrane. This concept, if it can be used as a general design principle for 
other particle implementations, will be very powerful.
The cytosol represents a particularly attractive target for antigen-
encoding DNA, as well as for protein antigen. If materials approaches to 
cytosolic targeting can allow highly efficient DNA delivery concurrently 
with prolonged PRR activation, dendritic cells could become a very 
attractive target for DNA vaccination. Given the logistical advantages 
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Figure 5 | Examples of polymers used for endolysosomal delivery. 
a–d, Polymers sensitive to oxidation within the lysosome (a) or reduction 
within the endosome (b–d). a, Oxidation of a hydrophobic sulphide, 
ultimately to a hydrophilic sulphone, leads to dissociation of self-assembled 
vesicles of the macroamphiphiles, which after oxidation are only hydrophilic 
and no longer amphiphilic48. b, Reduction of a disulphide link between the 
hydrophobic and hydrophilic blocks of a vesicle-forming macroamphiphile 
leads to vesicle rupture35. c, Reduction of an AB multiblock polymer leads 
to dissociation of a complex with DNA in the endosome50. d, Reduction 
of an analogous peptide-crosslinked DNA particle leads to DNA 
release51. e–f, Polymers sensitive to hydrolysis during acidification of the 
endolysosome, utilizing orthoesters (e) and ketals (f). R and Rʹ are usually 
alkyl groups, to adjust the hydrophobicity of the material.
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of delivery of antigen-encoding DNA (speed of production, cost and 
stability) relative to those of delivery of protein antigen, the attraction 
of such approaches for counteracting pathogens that vary seasonally 
(such as influenza virus) and pathogens that mainly affect the develop-
ing world is considerable.
Materials to trigger immune-specific functions
Now that we have introduced the systems by which to deliver antigens 
and danger signals to specific cellular and subcellular compartments, 
we consider how the materials affect dendritic cells either directly or 
indirectly, for example through mediation by protein–material inter-
actions or through a delivered biomolecular payload (although much 
of this, with the exception of the antigen, has been addressed above). 
Because PRRs are fundamental to the initiation of immunity, owing to 
their mediation of the recognition of PAMPs and DAMPs, biomaterials 
are being implemented to deliver natural or synthetic immunomodula-
tory agents to these receptors. However, the material itself may also be 
intrinsically biologically active, by virtue of its particulate character or 
as a result of protein interactions at the biomaterial surface.
The role of particle size and shape
As discussed above, particle size can control the biological transport and 
hence the bioavailability of a material to a remarkable degree, for exam-
ple through the tissue interstitium or across a mucosal barrier. However, 
material size characteristics may also be an important determinant of a 
material’s immunological activity. For example, the most common adju-
vants in clinical use are insoluble aluminium phosphates (alum), which 
form aggregates with the protein antigen and create an antigen depot. 
These particles, which might be considered chemically inert, enhance 
cellular IL-1β secretion62 by means of NALP3 (NACHT domain-, leu-
cine-rich repeat-, and PYD-containing protein 3, also known as NLRP3; 
ref. 63) to induce antibody-mediated protective immunity; therefore, 
the particles are themselves intrinsically recognized as a sign of danger. 
Because material particles can be both effective and economical, under-
standing and engineering this effect is of great interest. Recent work sug-
gests that this is possible, with evidence that polymeric microparticles 
endocytosed by dendritic cells trigger the inflammasome by means of 
NALP3 and, in concert with endogenous signals, induce both humoral 
and cellular immunity64. In vitro, inflammasome-activation-associated 
IL-1β secretion by dendritic cells in response to particle treatment (in 
addition to LPS stimulation) was size dependent and maximal at parti-
cle diameters between 400 and 1,000 nm (ref. 64). Given the <100-nm 
size limit for interstitial transport to access the lymph nodes, where large 
number of dendritic cells reside, the engineering of nanoscale particles to 
activate the inflammasome efficiently warrants further study.
Particle shape may also be important; for example, for micrometre-
scale particles the ability of macrophages to phagocytose a particle 
depends more on its shape than on its size65. This phenomenon is deter-
mined by actin mechanics at the points of particle contact. These results 
raise the intriguing possibility that shape may have such a role, either in 
uptake or in APC activation, at shorter length scales as well.
The role of particle hydrophobicity
Within the diverse family of TLR4-ligand and TLR2-ligand PAMPs 
(including LPS, lipopeptide and peptidoglycan) and DAMPs (including 
hyaluronan fragments, heat-shock proteins and fibronectin), an under-
lying biochemical thread may be the presence of hydrophobic domains, 
suggesting hydrophobicity to be a universal sign of danger sensed by 
TLRs18. Exploiting this connection may be of great interest as a poten-
tially economical strategy by which to ligate hydrophobicity-sensing 
PRRs and possibly avoid costly conjugation schemes for recombinant 
protein ligands or synthetic PRR ligands. The supramolecular organi-
zation of biomacromolecules that contain hydrophobic domains and 
have the capacity to hide or expose these hydrophobic patches seems 
to determine their ability to activate immunity18.
Given that microparticle formulations can be formed by nanoscale 
self-assembly of hydrophobic microdomains, approaches could be 
designed to control the degree of nanoparticulate hydrophobic-domain 
exposure, to exploit such a mechanism. However, the task of preserv-
ing a hydrophobic material surface once exposed is difficult: in the 
presence of protein in the biological environment, protein adsorption 
can rapidly obscure hydrophobic interfaces. From the perspective of 
inducing immunity, adsorption may have some advantages; the roles of 
immuno regulatory molecules (such as scavenger receptors and comple-
ment component C1q) in controlling normal hydrophobic molecule 
transport and clearance rather than in initiating an immune response18, 
as well as in molecular recognition specificity in TLR4 ligation rather 
than in TLR2 ligation (as these ligands induce TH1-type and TH2-type 
responses, respectively), remain to be elucidated to determine materials 
design guidelines for such a strategy. Thus, materials hydrophobicity 
may itself be a danger signal or may be interpreted by dendritic cells 
through the intermediating layer of adsorbed plasma proteins.
Complement activation
Whereas hydrophobicity in materials modulates relatively nonspecific 
protein adsorptive interactions, certain materials features can mimic 
features of pathogen surfaces to activate innate immune pathways. 
One such recognition cascade is complement, the alternative pathway 
of which recognizes certain primary hydroxyls66 and other surface 
nucleophiles67 to react at the site of a strained thioester in C3, forming 
material-bound activation product C3b68. Although much biomaterials 
research seeks to avoid such interactions, immunobioengineering can 
exploit complement activation, particularly in light of the variety of 
ways in which complement can affect innate and adaptive immunity69,70. 
Notably, the C3 activation products C3d and C3b have been shown 
to be molecular adjuvants capable of inducing strong antigen-specific 
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Figure 6 | Examples of polymers used for cytosolic delivery. a, Polypropyl 
acrylic acid disrupts membranes in a pH-dependent manner, with 
membranolytic activity at about the pH of early endosomes (~6.5). A block 
co-polymer is shown, of polypropyl acrylic acid and a monomer linked 
through a disulphide bond to the antigen, which can be released in the 
reductive environment of the endosome56. b, Crosslinked particles that 
are hydrolytically sensitive at endosomal pH, releasing a cell-penetrating 
peptide (CPP, which consists of polyarginine57), are formed by inverse 
emulsion polymerization of acrylamide, a CPP-grafted acrylamide 
and a ketal-containing bisacrylamide crosslinker, yielding the polymer 
shown here. Hydrolysis both degrades the crosslinks in the polymer 
and releases the CPP, destabilizing the endosome. c, The proton-sponge 
effect58 for endosomal disruption, and thus cytosolic delivery, has been 
implemented in core–shell nanoparticles by first polymerizing particles 
of diethylaminoethyl methacrylate and then sequentially polymerizing 
aminoethyl methacrylate, both with crosslinking59. One monomer forms 
the core (left), and one forms the corona, or shell (right).
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humoral immunity71–73, and materials have been developed to exploit 
C3 activation for adaptive immunity28.
Studies suggest that surface biochemistry such as sulphation may 
control the activation and deposition of complement species on cel-
lular or material surfaces by controlling the adsorption of complement 
factor H (CFH) and CFD74,75. Generating complement-opsonized par-
ticulates in situ by modulating material surface chemistry may therefore 
represent an inexpensive and powerful strategy to harness the molecu-
lar adjuvant properties of C3b and C3d. Interestingly, C1q, which binds 
to immunoglobulin on antigen ligation, also binds to hydrophobic mol-
ecules or aggregates such as LPS and liposomes18. Hence, the incorpo-
ration of hydrophobic domains could activate complement through 
the classical pathway to use the immunomodulatory properties of C2 
and C4.
Functionalization and encapsulation
We have seen that the biological context in which the targeted PRR 
is encountered by the material (for example at the cell surface or in 
the endosome) must be considered when designing materials deliv-
ering bioavailable molecules for PRR ligation. In addition, the ben-
efits of antigen display relative to encapsulation and of danger-signal 
co-encapsulation relative to co-delivery must be considered. For 
polymers that degrade too slowly for antigen encapsulation schemes, 
such as polylactic-co-glycolic acid, adsorption of antigen onto bio-
material particles may be more beneficial76. Within these systems, 
co-encapsulation of PAMPs, such as CpG oligonucleotides or TLR4 
ligands, is much more beneficial than co-administration, providing 
support for prolonged stimulation of dendritic cells after antigen col-
lection77–80. Indeed, when dendritic cells encounter both self antigen 
and pathogen-derived antigen, they use the coexistence of antigen and 
TLR ligand within the same endosome to distinguish between the two 
and enhance presentation of the pathogen-derived antigen on MHC 
class II molecules81. Bringing the antigen together with the PAMP, so 
as to model the situation found in the pathogen, therefore seems to be 
a sound design principle.
Materials as models for basic immunobiology
When immune cells interact with pathogens, or with each other, they 
do so in a complex display of a number of molecular mediators of 
antigen uptake, processing, presentation and activation. The challenge 
of teasing out molecular mechanisms from this process in its full com-
plexity can be daunting. Materials science in immunobioengineering 
allows the development of tools with which to assess molecular and 
cellular hypotheses. Whereas the sections above highlight research 
goals with translational ends, here we briefly touch on some that are 
more basic and mechanistic.
One opportunity for biomaterials research in immunobioengineer-
ing is the creation of synthetic pathogens for the study of dendritic-cell 
activation and downstream interactions with T cells that trigger adap-
tive immunity. Because dendritic cells have evolved to recognize such 
a diverse array of PAMPs, and because a number of such PAMPs are 
found in any one pathogen, it is difficult to study the molecular inter-
actions in simple, isolated systems. Biomaterials can provide a blank 
slate on which antigen and a defined set of PAMPs can be displayed in 
defined amounts for mechanistic investigation. As an example, we refer 
to the previously mentioned study on nanoparticle-induced activation 
of complement by means of surface-tethered PEG, in which comple-
ment was the only DAMP in the absence of any pathogen-associated 
signals28. Investigation of the pairwise interactions of particle size and 
complement activation demonstrated that complement is a powerful 
trigger of humoral and cellular immunity as long as the complement-
decorated particles are small enough (<50 nm in diameter) to enter 
the lymphatics and thus target lymph-node APCs28. Many other such 
mechanistic studies could use biomaterials as model systems, con-
trolling the destination of PAMP presentation (plasma membrane or 
endolysosome, or both) and the identity of the PAMPs (for example 
with multiple TLR ligands), with independent control of the numbers 
of PAMP molecules, their clustering and spatial organization and even 
their duration of exposure.
Investigating the interactions between immune cells themselves 
presents another interesting challenge for materials science in immuno-
bioengineering. For example, when activated dendritic cells present 
their antigen to T cells, a spatially organized structure referred to as 
the immunological synapse is created, in which the peptide-antigen-
loaded MHC molecule on the dendritic cell is presented to the TCR on 
the T cell; this receptor pair is organized after cellular contact such that 
the peptide–MHC–TCR pair (one receptor on each of the two cells) is 
clustered and is surrounded by an adhesion-receptor pair consisting of 
intercellular adhesion molecule 1 (ICAM1) on the dendritic cell bind-
ing to lymphocyte function-associated antigen 1 (LFA1) on the T cell82. 
It was previously unknown whether this evolving geometric patterning 
was required for the function of the immunological synapse or was 
only associated with it. Using supported lipid membranes in which 
bound peptide–MHC and ICAM1 could freely move laterally, a func-
tional immunological synapse could be formed, but when barriers were 
created to limit lateral reorganization of peptide–MHC and ICAM1, 
function was inhibited83; this suggested that the biological structuring 
is required for function. Likewise, when a TCR ligand was lithographi-
cally patterned in spots surrounded by ICAM1, a functional immuno-
logical synapse resulted, whereas when the geometry was reversed, 
no such function was possible84. In both of these examples, sophisti-
cated materials science approaches allowed well-controlled models of 
immune-cell interactions to probe biological hypotheses.
Future prospects
Materials science has a great deal to offer the field of immunology: 
immunobioengineering of prophylactic and therapeutic vaccine 
platforms, and model systems with which to explore the molecular 
and cellular interactions between immune cells and pathogens (and 
between different classes of immune cell), are just a few examples 
of this. The application of materials science towards therapy and 
pro phylaxis is instructed by immunobiology, and we have shown 
how materials science can in return be used to instruct immuno-
biology. The key feature that materials offer is that of design: design 
for encapsulation, design for immobilization or release of one or 
several biomolecular regulators of immune interactions, design for 
material functionalities such as release or membrane disruption in 
particular parts of the cell, and design for doing this in particular 
cellular and tissue targets. Some avenues may be more fruitful than 
others. Functional polymersomes are particularly attractive, in that 
both antigen and danger-signal payloads may be incorporated in the 
watery vesicle core, and other danger signals or targeting ligands may 
be attached to the polymersome surface or within the hydrophobic 
leaflet of the membrane. With materials chemistries leading to dis-
ruption and release within the endosome, and even destabilization of 
the endosomal membrane itself, a means of delivery for presentation 
by both MHC class II molecules and MHC class I molecules seems 
within reach. Still more interesting is the possibility of combining such 
means with physiological routes for delivery, for example by using 
ultrasmall self-assembled nanostructures to deliver such advanced 
materials directly to the lymphatics or to lymphoid tissue associated 
with the mucosae.
Clearly, even with the objective of vaccination described above, much 
work remains to be done, in that only very early implementations are 
clinically available or are in advanced stages of testing, rather than still 
being researched. As our understanding of immunobiology grows, so 
will the range of principles for the design of materials and material–
biomolecular conjugates used in immunotherapeutics. Moreover, the 
design principles will be different in various contexts: for example, in 
therapeutic vaccines against cancer, complex materials and formu-
lations may be contemplated, as cost does not present a major con-
sideration. By contrast, vaccination in a global context places severe 
constraints on logistics (wet formulations and unrefrigerated storage), 
use (preferably needle-free administration routes and few doses) and 
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cost (materials that can be easily manufactured and contain a minimal 
number of biological molecules). Although constraints are an annoy-
ance from a design perspective, they can also present exciting intellec-
tual challenges for the materials scientist and the immunobioengineer. 
The opportunity to combine possibilities for translation with those of 
using materials systems to learn more about the underpinning science, 
immunobiology, is also tremendously exciting. ■
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